Literature DB >> 3026241

Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.

P C Appelbaum, M R Jacobs, S K Spangler, S Yamabe.   

Abstract

The in vitro activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with six beta-lactams against 88 beta-lactamase-producing anaerobes were determined. When combined with the beta-lactams, the three beta-lactamase inhibitors showed no synergy against the 10 Bacteroides fragilis homology group II strains. When the beta-lactams were combined with the inhibitors, their geometric mean MICs against the remaining 78 strains were reduced from 4.2 to 150.2 micrograms/ml to 0.2 to 12.9 micrograms/ml. The activity of the beta-lactams combined with the beta-lactamase inhibitors was significantly greater than that of the beta-lactams alone against all groups except B. fragilis homology group II, with 76 to 100% of the strains susceptible to ampicillin plus inhibitor and greater than or equal to 90% susceptible to the other combinations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026241      PMCID: PMC176535          DOI: 10.1128/AAC.30.5.789

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.

Authors:  A L Barry; R N Jones; R R Packer
Journal:  J Antimicrob Chemother       Date:  1986-01       Impact factor: 5.790

2.  Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

Authors:  L Gutmann; M D Kitzis; S Yamabe; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

3.  Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.

Authors:  M A Crosby; D W Gump
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

4.  The beta-lactamases of Bacteroides species.

Authors:  R Timewell; E Taylor; I Phillips
Journal:  J Antimicrob Chemother       Date:  1981-02       Impact factor: 5.790

5.  Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Authors:  S C Aronoff; M R Jacobs; S Johenning; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

6.  Characterization of a new beta-lactamase from Fusobacterium nucleatum by substrate profiles and chromatofocusing patterns.

Authors:  K Tunér; L Lindqvist; C E Nord
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

7.  Beta-lactamase-producing isolates of Bacteroides species from children.

Authors:  I Brook; L Calhoun; P Yocum
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

8.  The effect of clavulanic acid on the susceptibility of Bacteroides fragilis to three acyl-ureidopenicillins, ampicillin and carbenicillin.

Authors:  C N Simpson; J P Maskell; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-08       Impact factor: 5.790

9.  Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics.

Authors:  J Wüst; T D Wilkins
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

10.  In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.

Authors:  H M Wexler; B Harris; W T Carter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

View more
  36 in total

1.  In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.

Authors:  H M Wexler; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

2.  Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance.

Authors:  P C Appelbaum; A Philippon; M R Jacobs; S K Spangler; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Authors:  N A Kuck; N V Jacobus; P J Petersen; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

4.  Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

Authors:  R J Fass; R B Prior
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

8.  Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content.

Authors:  I Podglajen; J Breuil; I Casin; E Collatz
Journal:  J Bacteriol       Date:  1995-09       Impact factor: 3.490

Review 9.  Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.

Authors:  P Charbonneau
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

Review 10.  Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H A Friedel; D M Campoli-Richards; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.